Researcher
Ann Gils
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → 31 Aug 2019
Projects
1 - 10 of 18
- BIOLOPTIM: implementing therapeutic drug monitoring of biologics for psoriasis and hidradenitis suppurativaFrom1 Oct 2018 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Mass cytometry by time-of-flight: next-generation flow cytometry for multiplexed single cell analysisFrom1 May 2018 → 30 Apr 2022Funding: FWO Medium Size Research Infrastructure
- Improving treatment outcomes for patients with chronic inflammatory diseases through identification of predictive biomarkers and therapeutic drug monitoring of new biologicalsFrom28 Aug 2017 → 31 Dec 2021Funding: FWO Strategic Basic Research Grant
- Immunogenicity of biological agents in inflammatory bowel disease and psoriasis: clinical relevance of early detection, characterization and prevention of anti-drug antibodies.From1 Oct 2016 → 30 Sep 2020Funding: FWO Applied Biomedical Research (TBM)
- Implementation of infliximab dosage regimen stratification through generalization/validation of rapid concentration-determining assays and generation of population-based pharmacokinetic/pharmacodynamic modelsFrom1 Oct 2015 → 30 Sep 2017Funding: IOF - Industrial Research Fund
- Pharmacometric models to improve therapeutic drug monitoring of monoclonal antibodies in the treatment of inflammatory bowel diseasesFrom1 Sep 2014 → 7 May 2019Funding: BOF - Doctoral projects
- Development, validation and clinical application of assas in order to perform blood concentration measurements of biological.From1 Oct 2013 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- Translating therapeutic drug monitoring of biopharmaceuticals into individualised care of inflammatory bowel disease patients through pharmacometric modelling en farmaco-economic evaluation.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
- Development and validation of rapid assays to quantify infliximab trough levels and antibodies towards infliximab.From17 Sep 2012 → 31 Dec 2017Funding: IWT personal funding - strategic basic research grants
- Optimizing treatment of IBD patients with anti-TNFalpha biopharmaceuticals via pharmacokinetic monitoring of trough levels and calculating the cost-effectiveness of this trough level based therapy.From1 Jan 2012 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
Publications
21 - 30 of 229
- Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance(2019)
Authors: Ann Gils
Pages: 478 - 485 - Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases(2019)
Authors: Erwin Dreesen, Ann Gils
Pages: 131 - 141 - Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases.(2019)
Authors: Erwin Dreesen, Ann Gils
Pages: 131 - 141 - Optimising infliximab induction dosing for patients with ulcerative colitis(2019)
Authors: Erwin Dreesen, Ruben Faelens, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils, Thomas Bouillon
Pages: 782 - 795 - Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease(2019)
Authors: Bram Verstockt, Sare Verstockt, Brecht Creyns, Gert Van Assche, Ann Gils, Jan Ceuppens, Séverine Vermeire, Marc Ferrante, Christine Breynaert
Pages: 572 - 581 - Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information(2019)
Authors: Iris Detrez, Gert Van Assche, Séverine Vermeire, Marc Ferrante, Ann Gils
- Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study(2019)
Authors: Ina Gesquiere, Nele Steenackers, Matthias Lannoo, Veerle Foulon, Ann Mertens, Ann Gils, Jan de Hoon, Patrick Augustijns, Christophe Matthys, Bart Van Der Schueren
Pages: 68 - 73 - Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases(2018)
Authors: Erwin Dreesen, Bram Verstockt, Sumin Bian, Magali de Bruyn, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 1937 - + - Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease(2018)
Authors: Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, Gert Van Assche, Marc Ferrante, Ann Gils, Séverine Vermeire
Pages: 1316 - 1325 - Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply(2018)
Authors: Erwin Dreesen, Ann Gils
Pages: 1029 - 1030
Patents
1 - 3 of 3
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)